Tracker

CDSCO approvals

CDSCO's list of new drug and clinical trial approvals holds 203 permission letters dated 2026, from January 1, 2026 to November 2, 2026. GCT is the most common kind of permission, with 73. Each row gives the company, product, kind of permission, date and a link to the letter, and CDSCO's file number where its text gives it.

From CDSCO's CT Approvals list, read . Each product links to CDSCO's PDF of its letter. The date is the one CDSCO gives on its list; the file number is printed in the letter. Not stated: file number on 4 rows. The file number is not read from 38 scanned letters: we read a letter's text, not its image.

The kinds of permission are CDSCO's own. FDC is fixed-dose combination (CDSCO's guidance for its Subject Expert Committees, page 13); GCT is global clinical trial (CDSCO's FAQs on the New Drugs and Clinical Trials Rules, page 8); IND is Investigational New Drug (CDSCO's guidance for its Subject Expert Committees, page 3); rDNA is recombinant Deoxyribonucleic Acid (CDSCO's FAQs on the New Drugs and Clinical Trials Rules, page 3, which that page writes r-DNA).

November 2026

October 2026

September 2026

August 2026

July 2026

June 2026

May 2026

April 2026

March 2026

February 2026

January 2026